National Guideline Clearinghouse | Vemurafenib for treating locally advanced or metastatic BRAF V600 mutation-positive malignant melanoma.

full-text:
National Guideline Clearinghouse | Vemurafenib for treating locally advanced or metastatic BRAF V600 mutation-positive malignant melanoma.

March 25, 2013

Guideline Title Vemurafenib for treating locally advanced or metastatic BRAF V600 mutation-positive malignant melanoma.   Bibliographic Source(s) National Institute for Health and Clinical Excellence (NICE). Vemurafenib for treating locally advanced or metastatic BRAF V600 mutation-positive malignant melanoma. London (UK): National Institute for Health and Clinical Excellence (NICE); 2012 Dec. 45 p. (Technology appraisal guidance; no. 269).   Guideline Status This is the current release of the guideline.